Madrigal Pharmaceuticals (MDGL) Short-term Investments (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Short-term Investments for 17 consecutive years, with $546.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Short-term Investments fell 10.61% year-over-year to $546.0 million; the TTM figure through Jun 2026 stood at $546.0 million (down 10.61% YoY), while the FY2025 annual figure was $784.9 million, down 5.01% from the prior year.
• Short-term Investments fell to $546.0 million in Q2 2026 per MDGL's latest filing, from $585.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $826.2 million in Q4 2024 and bottomed at $27.2 million in Q4 2022.
• Historically, Short-term Investments has averaged $455.1 million across 5 years, with a median of $540.1 million in 2023.
• Annual changes were most pronounced in 2022 — Short-term Investments slumped 88.37% — and 2023, when it surged 1862.23%.
• Madrigal Pharmaceuticals' Short-term Investments stood at $27.2 million in 2022, then soared by 1862.23% to $534.2 million in 2023, then soared by 54.66% to $826.2 million in 2024, then slipped by 5.01% to $784.9 million in 2025, then tumbled by 30.43% to $546.0 million in 2026.
• Business Quant data shows MDGL's Short-term Investments at $546.0 million in Q2 2026, $585.7 million in Q1 2026, and $784.9 million in Q4 2025.